Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression

Experimental Cell Research

Volumn 316, Issue 19, 2010, Pages 3197-3206

  McDonald, Gail T ^a   Sullivan, Richard ^a   Paré, Geneviève C ^a   Graham, Charles H ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Chemoresistance; PI3K; Proliferation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; VINCRISTINE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; MORPHOLINE DERIVATIVE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; COLON CARCINOMA; ENZYME INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; LUNG CARCINOMA; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR CELL; TUMOR RESISTANCE; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CLONE; CELL CYCLE; DRUG EFFECTS; DRUG RESISTANCE; FLOW CYTOMETRY; GENE SILENCING; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMONES; CLONE CELLS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HUMANS; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING;

EID: 77958082324     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.08.007     Document Type: Article

References (41)

1. Martin G.S. Cell signaling and cancer. Cancer Cell 2003, 4:167-174.
2. Crabbe T., Welham M.J., Ward S.G. The PI3K inhibitor arsenal: choose your weapon!. Trends Biochem. Sci. 2007, 32:450-456.
3. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
4. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4:988-1004.
5. Okkenhaug K., Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 2003, 3:317-330.
6. Katso R., Okkenhaug K., Ahmadi K., White S., Timms J., Waterfield M.D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 2001, 17:615-675.
7. Crowell J.A., Steele V.E., Fay J.R. Targeting the AKT protein kinase for cancer chemoprevention. Mol. Cancer Ther. 2007, 6:2139-2148.
8. Krasilnikov M.A. Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry (Mosc) 2000, 65:59-67.
9. Zhu Q., Youn H., Tang J., Tawfik O., Dennis K., Terranova P.F., Du J., Raynal P., Thrasher J.B., Li B. Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 2008, 27:4569-4579.
10. Hu L., Hofmann J., Lu Y., Mills G.B., Jaffe R.B. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002, 62:1087-1092.
11. Clark A.S., West K., Streicher S., Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 2002, 1:707-717.
12. Brognard J., Clark A.S., Ni Y., Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001, 61:3986-3997.
13. Hu L., Zaloudek C., Mills G.B., Gray J., Jaffe R.B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res. 2000, 6:880-886.
14. Takeda A., Osaki M., Adachi K., Honjo S., Ito H. Role of the phosphatidylinositol 3'-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas 2004, 28:353-358.
15. Shingu T., Yamada K., Hara N., Moritake K., Osago H., Terashima M., Uemura T., Yamasaki T., Tsuchiya M. Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor. J. Neurosurg. 2003, 98:154-161.
16. Tamburini J., Elie C., Bardet V., Chapuis N., Park S., Broet P., Cornillet-Lefebvre P., Lioure B., Ugo V., Blanchet O., Ifrah N., Witz F., Dreyfus F., Mayeux P., Lacombe C., Bouscary D. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 2007, 110:1025-1028.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
18. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 1995, 184:39-51.
19. Hayakawa M., Kaizawa H., Moritomo H., Koizumi T., Ohishi T., Okada M., Ohta M., Tsukamoto S., Parker P., Workman P., Waterfield M. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. 2006, 14:6847-6858.
20. Cully M., You H., Levine A.J., Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006, 6:184-192.
21. Ng S.S.W., Tsao M.S., Chow S., Hedley D.W. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000, 60:5451-5455.
22. Gottschalk A.R., Doan A., Nakamura J.L., Stokoe D., Haas-Kogan D.A. Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:1221-1227.
23. Li D.M., Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15406-15411.
24. Arafa E-S.A., Zhu Q., Barakat B.M., Wani G., Zhao Q., El-Mahdy M.A., Wani A.A. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res. 2009, 69:8910-8917.
25. Liang J., Ge F., Guo C., Luo G., Wang X., Han G., Zhang D., Wang J., Li K., Pan Y., Yao L., Yin Z., Guo X., Wu K., Ding J., Fan D. Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells. FEBS J. 2009, 276:685-694.
26. Wirbelauer C., Sutterluty H., Blondel M., Gstaiger M., Peter M., Reymond F., Krek W. The F-box protein Skp2 is a ubiquitylation target of a Cul1-based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts. EMBO J. 2000, 19:5362-5375.
27. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
28. Liang J., Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2:339-345.
29. Chabner B.A., Roberts T.G. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 2005, 5:65-72.
30. Viglietto G., Motti M.L., Bruni P., Melillo R.M., D'Alessio A., Califano D., Vinci F., Chiappetta G., Tsichlis P., Bellacosa A., Fusco A., Santoro M. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 2002, 8:1136-1144.
31. Oh S.Y., Park K.S., Kim J.A., Choi K.Y. Differential modulation of zinc-stimulated p21(Cip/WAF1) and cyclin D1 induction by inhibition of PI3 kinase in HT-29 colorectal cancer cells. Exp. Mol. Med. 2002, 34:27-31.
32. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
33. St Croix B., Florenes V.A., Rak J.W., Flanagan M., Bhattacharya N., Slingerland J.M., Kerbel R.S. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med. 1996, 2:1204-1210.
34. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 2008, 11:32-50.
35. Yu H.G., Ai Y.W., Yu L.L., Zhou X.D., Liu J., Li J.H., Xu X.M., Liu S., Chen J., Liu F., Qi Y.L., Deng Q., Cao J., Liu S.Q., Luo H.S., Yu J.P. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int. J. Cancer 2008, 122:433-443.
36. Lee C.M., Fuhrman C.B., Planelles V., Peltier M.R., Gaffney D.K., Soisson A.P., Dodson M.K., Tolley H.D., Green C.L., Zempolich K.A. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin. Cancer Res. 2006, 12:250-256.
37. Wang X., McCullough K.D., Franke T.F., Holbrook N.J. Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J. Biol. Chem. 2000, 275:14624-14631.
38. Kauffmann-Zeh A., Rodriguez-Viciana P., Ulrich E., Gilbert C., Coffer P., Downward J., Evan G. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997, 385:544-548.
39. Wan Y.S., Wang Z.Q., Shao Y., Voorhees J.J., Fisher G.J. Ultraviolet irradiation activates PI 3-kinase/AKT survival pathway via EGF receptors in human skin in vivo. Int. J. Oncol. 2001, 18:461-466.
40. West K.A., Castillo S.S., Dennis P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat. 2002, 5:234-248.
41. Zhao Y., You H., Yang Y., Wei L., Zhang X., Yao L., Fan D., Yu Q. Distinctive regulation and function of PI 3K/Akt and MAPKs in doxorubicin-induced apoptosis of human lung adenocarcinoma cells. J. Cell. Biochem. 2004, 91:621-632.